Clopidogrel‐Based Versus Aspirin‐Based Double Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation Patients: Results of the ASAF‐PCI Registry
Catheterization and Cardiovascular Interventions · 2026-11-19
DOI: 10.1002/ccd.71038 ↗At a glance
Journal article in Catheterization and Cardiovascular Interventions, published online on 2026-11-19. Written by Riccardo Panevino and 11 co-authors. 34 references.
Abstract (original language)
Background
In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), current guidelines recommend a brief period of triple antithrombotic therapy (TAT) consisting of an oral anticoagulant (OAC), aspirin and clopidogrel, followed by double antithrombotic therapy (DAT) with OAC plus clopidogrel. Evidence on aspirin as an alternative to clopidogrel within DAT remains limited.
Aims
The present analysis aimed at describing contemporary use of aspirin‐ versus clopidogrel‐based DAT and to compare 12‐month clinical outcomes.
Methods
In this multicenter, observational study, consecutive patients with AF undergoing PCI between January 2019 and December 2023 and discharged on DAT with OAC plus aspirin or clopidogrel were included. The primary endpoint was the 12‐month incidence of net adverse clinical events (NACE), composite of all‐cause death, non‐fatal myocardial infarction (MI), non‐fatal stroke, urgent revascularization, and major bleeding. Secondary composite and individual endpoints were also assessed. Multivariable logistic regression was used to adjust for baseline imbalances.
Results
Among 445 patients, 291 (65.4%) were discharged on clopidogrel‐based DAT and 154 (34.6%) on aspirin‐based DAT. Baseline characteristics were largely comparable. NACE occurred in 15.1% versus 13.6% of patients (OR 1.13, 95% CI 0.64–1.98; p = 0.674), with no significant difference after multivariable adjustment (adjusted OR 1.15, 95% CI 0.59–2.26; p = 0.677). No significant between group differences were observed for secondary composite or individual efficacy and safety endpoints.
Conclusions
In this real‐world cohort of AF patients undergoing PCI, aspirin‐ and clopidogrel‐based DAT with OAC were not associated with significantly different 12‐month outcomes. These hypothesis‐generating findings require confirmation in adequately powered randomized trials.
Cite
APA
Panevino, R., Pompei, G., Fabbri, E., Sanna, S., Casu, G., Ottani, F., Pizzi, C., Tarantino, F., Santarelli, A., Grilli, R., Diemberger, I., & Rubboli, A. (2026). Clopidogrel‐Based Versus Aspirin‐Based Double Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation Patients: Results of the ASAF‐PCI Registry. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.71038
Vancouver
Panevino R, Pompei G, Fabbri E, Sanna S, Casu G, Ottani F, et al. Clopidogrel‐Based Versus Aspirin‐Based Double Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation Patients: Results of the ASAF‐PCI Registry. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.71038
BibTeX
@article{Panevino2026,
author = {Panevino, Riccardo and Pompei, Graziella and Fabbri, Elisabetta and Sanna, Sebastiano and Casu, Gavino and Ottani, Filippo and Pizzi, Carmine and Tarantino, Fabio and Santarelli, Andrea and Grilli, Roberto and Diemberger, Igor and Rubboli, Andrea},
title = {Clopidogrel‐Based Versus Aspirin‐Based Double Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation Patients: Results of the ASAF‐PCI Registry},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
doi = {10.1002/ccd.71038}
}
EUVIMED